Novo Nordisk’s weight-loss drugs pose small risk of severe stomach complications: study

People who use Novo Nordisk’s popular weight-loss drugs are taking on a small risk of developing severe stomach problems, according to research conducted by the University of British Columbia and < | People who use Novo Nordisk’s popular weight-loss drugs are taking on a small risk of developing severe stomach problems, according to research conducted by the University of British Columbia. The investigation indicates a link between Novo’s GLP-1 products and gastroparesis, pancreatitis and bowel obstruction. Still, the investigators emphasized that the risk was very small. No Byline Policy

Editorial Guidelines

Corrections Policy

Source